| 翻訳と辞書 |
| Philip S. Portoghese ： ウィキペディア英語版 |
Philip S. Portoghese
Philip Salvatore Portoghese (born June 4, 1931) is an American chemist who has made notable contributions to the design and synthesis of ligands targeting opioid receptors. He is a Distinguished Professor of Medicinal Chemistry at the University of Minnesota, Twin Cities.〔http://www.pharmacy.umn.edu/medchem/faculty/directory/faculty/portoghese/home.html〕 He has also served as the Editor-in-chief of the Journal of Medicinal Chemistry since 1972.〔http://pubs.acs.org/page/jmcmar/profile.html〕
==Biography==
Portoghese was born on June 4, 1931 in Brooklyn, New York. He received a B.S. in pharmacy and then went on to obtain an M.S. degree in physical pharmacy in 1958. He then continued at the University of Wisconsin–Madison and obtained a Ph.D in pharmaceutical chemistry under the mentorship of Dr.Edward E. Smissman in 1961. He joined the faculty of the Department of Medicinal Chemistry at University of Minnesota in 1961, where he has served with distinction for over five decades. He is known internationally for designing several opioid ligands including β-funaltrexamine,〔P.S. Portoghese, D.L. Larson, L.M. Sayre, D.S. Fries and A.E. Takemori, A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities, J. Med. Chem. 23 (1980), p. 233.〕 naltrindole,〔Portoghese PS, Sultana M, Takemori AE. "Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist." European Journal of Pharmacology. 1988 Jan 27;146(1):185-6. PMID 2832195〕 norbinaltorphimine,〔Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sciences. 1987 Mar 30;40(13):1287-92. PMID 2882399〕 and naltriben.〔Sofuoglu M, Portoghese PS, Takemori AE. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 1991 May;257(2):676-80. PMID 1851833〕 He has pioneered the use of bivalent ligands to target opioid receptor complexes called homomers and heteromers.〔Erez, M., Takemori, A. E. & Portoghese, P. S. (1982) J. Med. Chem. 25, 847–849.〕〔Bhushan, R. G., Sharma, S. K., Xie, Z., Daniels, D. J.&Portoghese, P. S. (2004), J. Med. Chem. 47, 2969–2972.〕〔Daniels, D.J., et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proceedings of the National Academy of Sciences 102(52):19208-19213, 2005. (Text )〕〔http://www.nida.nih.gov/NIDA_notes/NNvol22N1/Basic.html〕 He was recently honored for 50 years of exemplary academic service by the University of Minnesota.〔http://www.pharmacy.umn.edu/news/portoghesesymp/home.html〕 In 2007, he was inducted into the Hall of Fame of the American Chemical Society (ACS) Division of Medicinal Chemistry.〔http://www.acsmedchem.org/halloffame.html〕 Dr. Portoghese served as Editor-in-chief of the ''Journal of Medicinal Chemistry'' from 1972 to 2012, making him one of the longest standing editors of an ACS journal.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Philip S. Portoghese」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|